Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Hypercalcemia Treatment Market: By Drug Class By Distribution Channels, By Geography
Hypercalcemia Treatment Market size was valued at US$ 15.9 billion in 2022 and is poised to grow at a CAGR of 11.2% from 2023 to 2029. Hypercalcemia is a condition in which the calcium level in your blood is above typical. A lot of calcium in your blood can debilitate your bones, make kidney stones, and meddle with how your heart and mind function. Hypercalcemia is typically a consequence of overactive parathyroid organs. These four modest organs are arranged behind the thyroid organ. Different reasons for hypercalcemia incorporate growth, certain other therapeutic issue, a few meds, and taking excessively of calcium and vitamin D supplements. The expanding occurrences of surgeries, for example, hip and knee substitutions, will build the danger of hypercalcemia and drive the development prospects for the worldwide hypercalcemia treatment showcase in the up and coming years. The examination additionally demonstrates that the commonness of broken bone repair medical procedures, cardiovascular techniques, percutaneous coronary intercessions, joint substitution medical procedures, knee substitution medical procedures, hip substitution medical procedures, and instances of coronary course sidestep uniting will expand the odds of creating hypercalcemia post medical procedures. Therefore, the interest for hypercalcemia treatment medications will likewise increment amid the anticipated period. The worldwide hypercalcemia treatment market is fragmented and is characterized by the presence of nearby, local, and global merchants. The developing rate of endocrine issue, for example, hyperparathyroidism and kidney infections will push the interest for the creation of medications. The sellers in the market are progressively contending with each other in view of variables, for example, forceful evaluating and new signs. To infiltrate encourage into the hyperparathyroidism advertise, a few merchants are concentrating on leading broad research and formative exercises and pick up endorsements. Moreover, an extensive number of market players are likewise progressively creating compelling medicines for spasticity because of the high neglected restorative needs.
Study Period
2024-2030Base Year
2023CAGR
11.2%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The expanding occurrences of surgeries, for example, hip and knee substitutions, will build the danger of hypercalcemia and drive the development prospects for the worldwide hypercalcemia treatment showcase in the up and coming years. The examination additionally demonstrates that the commonness of broken bone repair medical procedures, cardiovascular techniques, percutaneous coronary intercessions, joint substitution medical procedures, knee substitution medical procedures, hip substitution medical procedures, and instances of coronary course sidestep uniting will expand the odds of creating hypercalcemia post medical procedures. Therefore, the interest for hypercalcemia treatment medications will likewise increment amid the anticipated period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 15.9 billion |
Market CAGR |
11.2% |
By Drug Class |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The hypercalcemia treatment market is projected to expand at a CAGR of 11.2% during the forecast period.
Pfizer, Inc. (U.S.), Sanofi (France), Boehringer Ingelheim (Germany), Novartis (Switzerland), GlaxoSmithKline plc (U.K.)
North America is the fastest-growing region for hypercalcemia treatment market
1. Executive Summary |
2. Global Hypercalcemia Treatment Market Introduction |
2.1.Global Hypercalcemia Treatment Market - Taxonomy |
2.2.Global Hypercalcemia Treatment Market - Definitions |
2.2.1.Drug Class |
2.2.2.Distribution Channel |
2.2.3.Region |
3. Global Hypercalcemia Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Hypercalcemia Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Hypercalcemia Treatment Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Bisphosphonates |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Calcimimetic Agents |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Calcitonin |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Denusomab |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Glucocorticoids |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6. Global Hypercalcemia Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospitals Pharmacies |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacies |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Online Pharmacies |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Hypercalcemia Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Hypercalcemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Bisphosphonates |
8.1.2.Calcimimetic Agents |
8.1.3.Calcitonin |
8.1.4.Denusomab |
8.1.5.Glucocorticoids |
8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospitals Pharmacies |
8.2.2.Retail Pharmacies |
8.2.3.Online Pharmacies |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Hypercalcemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Bisphosphonates |
9.1.2.Calcimimetic Agents |
9.1.3.Calcitonin |
9.1.4.Denusomab |
9.1.5.Glucocorticoids |
9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospitals Pharmacies |
9.2.2.Retail Pharmacies |
9.2.3.Online Pharmacies |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
9.3.7. |
10. Asia Pacific (APAC) Hypercalcemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Bisphosphonates |
10.1.2.Calcimimetic Agents |
10.1.3.Calcitonin |
10.1.4.Denusomab |
10.1.5.Glucocorticoids |
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospitals Pharmacies |
10.2.2.Retail Pharmacies |
10.2.3.Online Pharmacies |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Hypercalcemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Bisphosphonates |
11.1.2.Calcimimetic Agents |
11.1.3.Calcitonin |
11.1.4.Denusomab |
11.1.5.Glucocorticoids |
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospitals Pharmacies |
11.2.2.Retail Pharmacies |
11.2.3.Online Pharmacies |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Hypercalcemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Bisphosphonates |
12.1.2.Calcimimetic Agents |
12.1.3.Calcitonin |
12.1.4.Denusomab |
12.1.5.Glucocorticoids |
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospitals Pharmacies |
12.2.2.Retail Pharmacies |
12.2.3.Online Pharmacies |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Pfizer, Inc. (U.S.) |
13.2.2.Sanofi (France) |
13.2.3.Boehringer Ingelheim (Germany) |
13.2.4.Novartis (Switzerland) |
13.2.5.GlaxoSmithKline plc (U.K.) |
13.2.6.Bristol-Myers Squibb (U.S.) |
13.2.7.Teva Pharmaceutical Industries Ltd. (Israel) |
13.2.8.Eli Lilly and Company (U.S.) |
14. Research Methodology |
15. Appendix and Abbreviations |
Key Market Players